September 09, 2024

LBBW Venture Capital GmbH

LBBW Venture Capital GmbH
Go back

Our latest News

discover more
Why pain persists long after injuries have healed

Why pain persists long after injuries have healed

Prof. Dr. Rohini Kuner of the Heidelberg Faculty of Medicine at Heidelberg University awarded the 2026 Jung Prize for Medicine Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the […]

read more
New HI-STEM Publication: A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells

New HI-STEM Publication: A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells

Rodríguez-Correa, E., Grünschläger, F., Nizharadze, T. et al. A kinetics-based model of haematopoiesis reveals extrinsic regulation of skewed lineage output from stem cells. Nat Cell Biol (2026). https://doi.org/10.1038/s41556-026-01958-0 https://www.nature.com/articles/s41556-026-01958-0 Abstract Haematopoietic stem cells (HSCs) display extensive molecular and functional heterogeneity. However, a cohesive model that explains the relationship and biological relevance of these diverse HSC states remains elusive. Here, […]

read more
Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp